Literature DB >> 33704717

Multi-Marker Immunomagnetic Enrichment of Circulating Melanoma Cells.

Aaron B Beasley1, Emmanuel Acheampong1, Weitao Lin1, Elin S Gray2.   

Abstract

Within the last decade, circulating tumor cells (CTCs) have emerged as a promising biomarker for prognostication, treatment monitoring, and detection of markers of treatment resistance, and their isolation can be used as a minimally invasive means of profiling tumors across multiple body sites. However, CTCs represent a minuscule fraction of the total circulating cells in a patient. Therefore, sensitive isolation methods are needed for the detection and downstream analysis of these cells. Herein we describe a sensitive method for melanoma CTC isolation using a multi-marker immunomagnetic bead method. This method has been purposely optimized to detect CTCs in melanoma patients.

Entities:  

Keywords:  Circulating tumor cells (CTCs ); Immunomagnetic beads; Multi-marker

Mesh:

Substances:

Year:  2021        PMID: 33704717     DOI: 10.1007/978-1-0716-1205-7_16

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  15 in total

1.  Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma.

Authors:  Leila Khoja; Patrick Shenjere; Clare Hodgson; Jackie Hodgetts; Glen Clack; Andrew Hughes; Paul Lorigan; Caroline Dive
Journal:  Melanoma Res       Date:  2014-02       Impact factor: 3.599

Review 2.  The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

Authors:  Massimo Cristofanilli; Jean-Yves Pierga; James Reuben; Alfred Rademaker; Andrew A Davis; Dieter J Peeters; Tanja Fehm; Franco Nolé; Rafael Gisbert-Criado; Dimitrios Mavroudis; Salvatore Grisanti; Mario Giuliano; Jose A Garcia-Saenz; Justin Stebbing; Carlos Caldas; Paola Gazzaniga; Luis Manso; Rita Zamarchi; Angela Fernandez de Lascoiti; Leticia De Mattos-Arruda; Michail Ignatiadis; Luc Cabel; Steven J van Laere; Franziska Meier-Stiegen; Maria-Teresa Sandri; Jose Vidal-Martinez; Eleni Politaki; Francesca Consoli; Daniele Generali; Maria Rosa Cappelletti; Eduardo Diaz-Rubio; Jonathan Krell; Sarah-Jane Dawson; Cristina Raimondi; Annemie Rutten; Wolfgang Janni; Elisabetta Munzone; Vicente Carañana; Sofia Agelaki; Camillo Almici; Luc Dirix; Erich-Franz Solomayer; Laura Zorzino; Lauren Darrigues; Jorge S Reis-Filho; Lorenzo Gerratana; Stefan Michiels; François-Clément Bidard; Klaus Pantel
Journal:  Crit Rev Oncol Hematol       Date:  2018-12-19       Impact factor: 6.312

3.  Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer.

Authors:  Matthew G Krebs; Robert Sloane; Lynsey Priest; Lee Lancashire; Jian-Mei Hou; Alastair Greystoke; Tim H Ward; Roberta Ferraldeschi; Andrew Hughes; Glen Clack; Malcolm Ranson; Caroline Dive; Fiona H Blackhall
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

4.  Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma.

Authors:  Leila Khoja; Paul Lorigan; Cong Zhou; Matthew Lancashire; Jessica Booth; Jeff Cummings; Raffaele Califano; Glen Clack; Andrew Hughes; Caroline Dive
Journal:  J Invest Dermatol       Date:  2012-12-06       Impact factor: 8.551

5.  Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells.

Authors:  Anja Ulmer; Oleg Schmidt-Kittler; Jörg Fischer; Ulf Ellwanger; Gernot Rassner; Gert Riethmüller; Gerhard Fierlbeck; Christoph A Klein
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

6.  Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).

Authors:  Alberto Fusi; Sandra Collette; Antonia Busse; Stefan Suciu; Anika Rietz; Mario Santinami; Wim H J Kruit; Alessandro Testori; Cornelis J A Punt; Angus G Dalgleish; Alan Spatz; Alexander M M Eggermont; Ulrich Keilholz
Journal:  Eur J Cancer       Date:  2009-09-28       Impact factor: 9.162

7.  Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells.

Authors:  James B Freeman; Elin S Gray; Michael Millward; Robert Pearce; Melanie Ziman
Journal:  J Transl Med       Date:  2012-09-15       Impact factor: 5.531

8.  Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment.

Authors:  Elin S Gray; Anna L Reid; Samantha Bowyer; Leslie Calapre; Kelvin Siew; Robert Pearce; Lester Cowell; Markus H Frank; Michael Millward; Mel Ziman
Journal:  J Invest Dermatol       Date:  2015-04-01       Impact factor: 8.551

9.  Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells.

Authors:  Carlos Alberto Aya-Bonilla; Michael Morici; Xin Hong; Ashleigh Cavell McEvoy; Ryan Joseph Sullivan; James Freeman; Leslie Calapre; Muhammad Adnan Khattak; Tarek Meniawy; Michael Millward; Mel Ziman; Elin Solomonovna Gray
Journal:  Br J Cancer       Date:  2020-02-10       Impact factor: 7.640

10.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

View more
  1 in total

1.  tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature.

Authors:  Paraskevi Karousi; Aristea-Maria Papanota; Pinelopi I Artemaki; Christine-Ivy Liacos; Dimitrios Patseas; Nefeli Mavrianou-Koutsoukou; Aikaterini-Anna Liosi; Maria-Anna Kalioraki; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Efstathios Kastritis; Meletios-Athanasios Dimopoulos; Andreas Scorilas; Evangelos Terpos; Christos K Kontos
Journal:  Biomedicines       Date:  2021-12-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.